Skip to main content
    T

    Traws Pharma Inc (TRAW)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.41
    +0.01 (+1.94%)

    Market Cap: $6.17M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    69%(27/39)
    Avg Surprise
    +278.32%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.20
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.63+68.3%
    60d ago$-0.36+44.4%
    30d ago$-0.36+44.4%
    7d ago$-0.36+44.4%
    Current$-0.20
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.12
    Range$-0.12 - $-0.12
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.12---
    Sep 26EST
    		-$-0.20---
    Jun 26
    Reported Aug 13
    		$-0.16$-0.22+27.27%Beat+0.0%
    Mar 26
    Reported Apr 15
    		$-0.52$-0.56+7.14%Beat-124.9%
    Dec 25
    Reported Dec 31
    		$-0.55$-0.54-2.67%Miss-102.1%
    Sep 25
    Reported Nov 13
    		$-0.34N/A+96.29%Beat+96.1%
    Jun 25
    Reported Aug 14
    		$-0.16N/A+98.17%Beat+99.9%
    Mar 25
    Reported May 15
    		$2.09$-0.27+888.68%Beat+141.8%
    Dec 24
    Reported Mar 31
    		$26.60$-0.25+10740.00%Beat+14100.0%
    Sep 24
    Reported Nov 14
    		$-8.81$-6.25-40.96%Miss-53.2%
    Jun 24
    Reported Aug 15
    		$-121.75$-6.25-1848.00%Miss-2335.0%
    Mar 24
    Reported Apr 1
    		$-5.00$-6.33+21.01%Beat+28.6%
    Dec 23
    Reported Mar 14
    		$-0.19$-0.25+24.00%Beat+26.9%
    Sep 23
    Reported Nov 14
    		$-5.75$-7.25+20.69%Beat+11.5%
    Jun 23
    Reported Aug 10
    		$-5.00$-7.81+35.98%Beat-5.3%
    Mar 23
    Reported May 15
    		$-7.00$-7.44+5.91%Beat-40.0%
    Dec 22
    Reported Mar 16
    		$-0.26$-0.26+0.00%Beat-52.9%
    Sep 22
    Reported Nov 14
    		$-6.50$-5.31-22.41%Miss-18.2%
    Jun 22
    Reported Aug 11
    		$-4.75$-4.94+3.85%Beat+29.6%
    Mar 22
    Reported May 11
    		$-5.00$-4.69-6.61%Miss-1566.7%
    Dec 21
    Reported Mar 17
    		$-0.17$-0.17+0.00%Beat+98.5%
    Sep 21
    Reported Nov 11
    		$-5.50$-8.17+32.68%Beat+51.1%
    Jun 21
    Reported Aug 12
    		$-6.75$-7.12+5.20%Beat+55.0%
    Mar 21
    Reported May 17
    		$-0.30$-0.45+33.33%Beat+97.3%
    Dec 20
    Reported Mar 11
    		$-11.25$-13.12+14.25%Beat-1078.3%
    Sep 20
    Reported Nov 12
    		$-11.25$-12.50+10.00%Beat+96.0%
    Jun 20
    Reported Aug 12
    		$-15.00$-11.25-33.33%Miss+93.3%
    Mar 20
    Reported May 14
    		$-11.25$-20.62+45.44%Beat+97.7%
    Dec 19
    Reported Mar 24
    		$1.15$-0.07+1742.86%Beat+217.3%
    Sep 19
    Reported Nov 12
    		$-281.25$-255.00-10.29%Miss+20.2%
    Jun 19
    Reported Aug 14
    		$-225.00$-330.00+31.82%Beat+42.9%
    Mar 19
    Reported May 14
    		$-483.75$-388.12-24.64%Miss-9385.3%
    Dec 18
    Reported Mar 26
    		$-0.98$-0.97-1.03%Miss+100.0%
    Sep 18
    Reported Nov 13
    		$-352.50$-435.00+18.97%Beat+91.2%
    Jun 18
    Reported Aug 14
    		$-393.75$-431.25+8.70%Beat+75.9%
    Mar 18
    Reported May 15
    		$-5.10$-0.39-1207.69%Miss+99.9%
    Dec 17
    Reported Mar 8
    		$-3318.75$-3867.19+14.18%Beat-614483.3%
    Sep 17
    Reported Nov 9
    		$-3993.75$-3895.31-2.53%Miss-
    Jun 17
    Reported Aug 14
    		$-1631.25N/A+59.91%Beat-
    Mar 17
    Reported May 15
    		$-6918.75$-5400.00-28.13%Miss-
    Dec 16
    Reported Mar 27
    		$-0.54N/A+96.40%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.26EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-433.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio0.93xQuick Ratio0.93x
    Trading Statistics
    Beta1.53Avg Volume1.49M
    52-Week High$3.1552-Week Low$0.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.47
    SMA 20$0.51
    SMA 50$0.53
    SMA 200$1.22
    EMA 10$0.45
    EMA 20$0.49
    EMA 50$0.56
    EMA 200$1.07

    MACD

    Line: -0.04Signal: -0.02Hist: -0.01

    ADX

    ADX: 19.5+DI: 22.6-DI: 27.6

    Aroon & PSAR

    Aroon Up40.0
    Aroon Down100.0
    PSAR$0.62

    Bollinger Bands

    Upper Band$0.64
    Lower Band$0.37
    %B Position5231%(Upper)
    Band Width0.13

    RSI (14-Day)

    Neutral
    32.4

    Momentum Oscillators

    Stoch %K3.3
    Stoch %D2.6
    Williams %R-94.2
    ROC (10d)-25.0%
    Momentum-0.14
    CCI (20d)-129.5
    MFI (14d)39.2

    Volatility Measures

    ATR (14d)$0.04(10.7%)
    StdDev (20d)0.07
    Hist Vol86.9%(High)

    Volume Flow

    VWAP$0.41
    OBV147.1M
    AD Line-78.7M
    CMF (20d)-0.323

    Volume Metrics

    Avg Vol (20d)1.6M
    Vol Ratio0.0x(Low)
    VWMA (20d)$0.55

    Pivot Points

    R3$0.44
    R2$0.43
    R1$0.42
    Pivot Point$0.40
    S1$0.39
    S2$0.38
    S3$0.36

    Advanced Oscillators

    TSI-23.95
    Ultimate Osc37.9
    KST-117.71

    Financial Data

    QuarterJun 2027Mar 2027Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    Total Revenue$0$0$0$0$0$2.62M$0$2.73M$57,000$57,000$57,000$57,000
    Cost of Revenue$0$0$0$0$0N/A$0$0$0$2,000$0$0
    Gross Profit$0$0$0$0$0$2.62M$0$2.73M$57,000$55,000$57,000$57,000
    Operating Expenses$3.17M$6.95M$4.05M$3.17M$6.95M$7.37M$4.05M$3.98M$5.26M$8.59M$8.59M$123.41M
    R&D$1.10M$4.91M$2.31M$1.10M$4.91M$5.04M$2.31M$2.29M$2.51M$5.11M$5.11M$121.43M
    SG&A$3.48M$2.03M$1.74M$3.48M$2.03M$2.33M$1.74M$1.69M$2.75M$3.48M$3.48M$1.98M
    Operating Income$-3,175,000$-6,946,000$-4,055,000$-3,175,000$-6,946,000$-7,368,000$-4,055,000$-1,249,000$-5,203,000$-8,536,000$-8,536,000$-123,348,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$159,000$3,000$0$0$0$0$0$0$0$0$0
    Income Before Tax$-2,960,000$-7,105,000$-4,058,000$-2,960,000$-7,105,000$-7,457,000$-4,058,000$-1,103,000$21.31M$-8,475,000$-8,536,000$-123,348,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,054,000$-7,107,000$-3,962,000$-3,054,000$-7,107,000$-7,443,000$-3,962,000$-915,000$21.49M$-8,475,000$-8,475,000$-123,143,000
    EBITDA$-2,916,000$-7,061,000$-4,043,000$-2,916,000$-7,061,000$-7,413,000$-4,043,000$-1,102,000$21.31M$-8,473,000$-8,534,000$-123,344,000
    EBIT$-2,960,000$-7,105,000$-4,058,000$-2,960,000$-7,105,000$-7,457,000$-4,058,000$-1,103,000$21.31M$-8,475,000$-8,536,000$-123,348,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TRAW

    News

    Form PRE 14A Traws Pharma Inc For: 10 October By Investing.com

    The article reports on the filing of Form PRE 14A by Traws Pharma Inc. on October 10. This brief piece, published by Investing.com...

    Investing.com India•10/10/26•Neutral

    Form PRE 14A Traws Pharma Inc For: 10 October By Investing.com

    This article reports that Traws Pharma Inc. filed a Form PRE 14A on October 10, 2026. The content provides a brief announcement of this filing...

    Investing.com Nigeria•10/10/26•Neutral

    Form PRE 14A Traws Pharma Inc For: 10 October By Investing.com

    This article announces the filing of Form PRE 14A by Traws Pharma Inc. for October 10. It is a very brief notification from Investing.com and includes the stock symbol TRAW with its current performance. The content...

    Investing.com Canada•10/10/26•Neutral

    H.C. Wainwright reiterates Neutral on Traws Pharma stock at $1

    H.C. Wainwright has reiterated a Neutral rating and $1.00 price target for Traws Pharma Inc. following its Q2 2026 update. The company is working to resubmit an updated toxicology package to the MHRA and resolve a U.S....

    Investing.com•8/19/26•Somewhat-Bearish

    H.C. Wainwright Maintains Traws Pharma(TRAW.US) With Hold Rating, Maintains Target Price $1

    H.C. Wainwright has reiterated its Hold rating for Traws Pharma (TRAW.US) and maintained its target price at $1. This indicates the analyst firm sees no immediate significant upside or downside for the stock based...

    Moomoo•8/19/26•Neutral

    TRAW Valuation and Fair Value

    P/E
    -0.3x
    P/B
    3.8x
    See GNG's fair value

    TRAW Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -433.4%

    TRAW Competitors

    CompanyTicker
    Enveric Biosciences IncENVB
    Reviva Pharmaceuticals Holdings Inc.RVPH
    Co-Diagnostics, Inc. Common StockCODX
    Zhongchao IncZCMD
    Neurosense Therapeutics LtdNRSN
    Healthcare Triangle IncHCTI
    Nutriband Inc. WarrantNTRBW
    WORK Medical Technology Group LTD Ordinary SharesWOK

    Sector: Healthcare

    TRAW Bull Case vs Bear Case

    Bull case

    • TRAW beat EPS estimates in 75.0% of its last 8 reported quarters.

    Bear case

    • TRAW's quarterly revenue changed -100.0% year over year.

    TRAW Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    153.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About TRAW

    Does TRAW pay dividends?

    Traws Pharma Inc (TRAW) does not currently pay a regular dividend.

    What is TRAW's market cap?

    Traws Pharma Inc (TRAW) has a market capitalization of $6.17M with a current stock price of $0.41.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In